Join the Oncology Voice Network. Join for Free
How to Start a Diversity Equity & Inclusion Program in Pharma
Provide 5 keywords for SEO search separated by commas

How to Start a Diversity Equity & Inclusion Program in Pharma


Share This Article


Summary

In this episode, Tara Gonzalez joins to discuss the intricacies of establishing Diversity, Equity, and Inclusion (DEI) programs within organizations. She shares insights from her background and outlines the challenges and strategies for initiating DEI initiatives. Tara emphasizes the importance of structuring DEI functions and engaging the entire company, while highlighting the role of external consultants in conducting needs assessments. The conversation covers best practices, the necessity of leadership buy-in, and the ongoing development of DEI efforts. Tara concludes with valuable advice for those looking to implement DEI programs, providing a comprehensive overview of this crucial topic.

This episode features Tara Gonzales, Vice President Medical Affairs discusses how to start a DEI program in Pharma
Tara shares….

👉 How she stood up a DEI program from scratch
👉 Why there is such a need for DEI programs
👉 What companies can expect as far as impact of a well run DEI program
👉 What it takes to build a positive culture in a company

Click for Source
Provide 5 keywords for SEO search separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Leveraging Creativity to Break into Your First MSL Role
Partner Avatar MSL Talk: Tom Caravela, Alec McCarthy

Leveraging Creativity to Break into Your First MSL Role

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Where Did My Interview Go Wrong?
Partner Avatar Tom Caravela

Where Did My Interview Go Wrong?

Explore OVN